MX2020002322A - Compuestos y composiciones para la inhibicion de ire1. - Google Patents
Compuestos y composiciones para la inhibicion de ire1.Info
- Publication number
- MX2020002322A MX2020002322A MX2020002322A MX2020002322A MX2020002322A MX 2020002322 A MX2020002322 A MX 2020002322A MX 2020002322 A MX2020002322 A MX 2020002322A MX 2020002322 A MX2020002322 A MX 2020002322A MX 2020002322 A MX2020002322 A MX 2020002322A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- compositions
- compounds
- disorder
- ire1
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 101100452784 Caenorhabditis elegans ire-1 gene Proteins 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000016192 Demyelinating disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762553320P | 2017-09-01 | 2017-09-01 | |
| PCT/US2018/049081 WO2019046711A2 (en) | 2017-09-01 | 2018-08-31 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING IRE1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020002322A true MX2020002322A (es) | 2020-10-05 |
Family
ID=65526075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002322A MX2020002322A (es) | 2017-09-01 | 2018-08-31 | Compuestos y composiciones para la inhibicion de ire1. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11649237B2 (enExample) |
| EP (1) | EP3675858B1 (enExample) |
| JP (1) | JP2020532589A (enExample) |
| KR (1) | KR20200066301A (enExample) |
| CN (1) | CN111526877B (enExample) |
| AU (1) | AU2018326721B2 (enExample) |
| BR (1) | BR112020004226A2 (enExample) |
| CA (1) | CA3074139A1 (enExample) |
| IL (1) | IL272845B2 (enExample) |
| MX (1) | MX2020002322A (enExample) |
| SG (1) | SG11202001609RA (enExample) |
| WO (1) | WO2019046711A2 (enExample) |
| ZA (1) | ZA202001320B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020059841A1 (ja) * | 2018-09-21 | 2020-03-26 | 国立大学法人 長崎大学 | プリオン病治療薬 |
| CA3131386A1 (en) * | 2019-02-27 | 2020-09-03 | Richard Keenan | Imidazolopyrazine compounds for ire1 inhibition |
| BR112021016974A2 (pt) * | 2019-02-27 | 2021-11-30 | Optikira Llc | Compostos de pirazolopiridina para inibição de ire1 |
| US20230331719A1 (en) * | 2020-08-07 | 2023-10-19 | Optikira, LLC | Pyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using Same |
| EP4243815A4 (en) * | 2020-11-13 | 2024-10-02 | The Regents of the University of California | IRE1ALPHA INHIBITORS AND USES THEREOF |
| JP2025504791A (ja) * | 2022-01-07 | 2025-02-19 | アンスティチュート、ナシオナル、ドゥ、ラ、サンテ、エ、ドゥ、ラ、ルシェルシュ、メディカル | ヒドロキシフェニル部分を含む化合物及びその使用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR057960A1 (es) * | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
| EP2283020B8 (en) | 2008-05-19 | 2012-12-12 | OSI Pharmaceuticals, LLC | Substituted imidazopyr-and imidazotri-azines |
| WO2011047384A2 (en) * | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
| CN103079558B (zh) | 2010-04-05 | 2025-09-12 | 上海复星医药产业发展有限公司 | IRE-1α抑制剂 |
| EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| MX2015003874A (es) * | 2012-09-26 | 2015-12-16 | Univ California | Modulacion de ire1. |
| WO2016004254A1 (en) * | 2014-07-01 | 2016-01-07 | The Regents Of The University Of California | Combined modulation of ire1 |
| WO2017152117A1 (en) | 2016-03-03 | 2017-09-08 | Cornell University | Small molecule ire1-alpha inhibitors |
| WO2018102751A1 (en) | 2016-12-02 | 2018-06-07 | Quentis Therapeutics, Inc. | Ire1 small molecule inhibitors |
-
2018
- 2018-08-31 KR KR1020207009201A patent/KR20200066301A/ko not_active Ceased
- 2018-08-31 SG SG11202001609RA patent/SG11202001609RA/en unknown
- 2018-08-31 AU AU2018326721A patent/AU2018326721B2/en not_active Ceased
- 2018-08-31 JP JP2020534804A patent/JP2020532589A/ja active Pending
- 2018-08-31 US US16/642,208 patent/US11649237B2/en active Active
- 2018-08-31 IL IL272845A patent/IL272845B2/en unknown
- 2018-08-31 BR BR112020004226-9A patent/BR112020004226A2/pt not_active Application Discontinuation
- 2018-08-31 EP EP18849820.8A patent/EP3675858B1/en active Active
- 2018-08-31 WO PCT/US2018/049081 patent/WO2019046711A2/en not_active Ceased
- 2018-08-31 CN CN201880066168.9A patent/CN111526877B/zh active Active
- 2018-08-31 CA CA3074139A patent/CA3074139A1/en active Pending
- 2018-08-31 MX MX2020002322A patent/MX2020002322A/es unknown
-
2020
- 2020-02-28 ZA ZA2020/01320A patent/ZA202001320B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN111526877A (zh) | 2020-08-11 |
| WO2019046711A2 (en) | 2019-03-07 |
| IL272845B1 (en) | 2023-08-01 |
| RU2020112425A3 (enExample) | 2022-03-31 |
| BR112020004226A2 (pt) | 2020-11-17 |
| EP3675858A4 (en) | 2021-03-17 |
| IL272845A (en) | 2020-04-30 |
| EP3675858A2 (en) | 2020-07-08 |
| US11649237B2 (en) | 2023-05-16 |
| EP3675858B1 (en) | 2023-04-26 |
| SG11202001609RA (en) | 2020-03-30 |
| ZA202001320B (en) | 2023-10-25 |
| US20200354367A1 (en) | 2020-11-12 |
| IL272845B2 (en) | 2023-12-01 |
| KR20200066301A (ko) | 2020-06-09 |
| AU2018326721A1 (en) | 2020-03-12 |
| RU2020112425A (ru) | 2021-10-04 |
| CN111526877B (zh) | 2023-08-25 |
| JP2020532589A (ja) | 2020-11-12 |
| WO2019046711A3 (en) | 2020-04-02 |
| CA3074139A1 (en) | 2019-03-07 |
| AU2018326721B2 (en) | 2022-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2019046711A3 (en) | Compounds and compositions for ire1 inhibition | |
| PH12021550558A1 (en) | Modulators of pnpla3 expression | |
| PH12018501716A1 (en) | Novel condensed pyrimidine compoun or salt thereof | |
| EA201892229A1 (ru) | Замещенные аминопуриновые соединения, содержащие их композиции и способы лечения с их применением | |
| EP4092119A3 (en) | Modulators of diacyglycerol acyltransferase 2 (dgat2) | |
| GEAP202115183A (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| PH12017500920A1 (en) | 4-oxo-3,4-dihydro-1,2,3-benzotriazine as modulators of gpr139 | |
| MX2025003294A (es) | Moduladores de la expresion de apol1 | |
| PH12019500196A1 (en) | Compounds and compositions and uses thereof | |
| PH12019502174A1 (en) | Modulators of pcsk9 expression | |
| SA519402288B1 (ar) | مركب بيريميدين واستخداماته الصيدلانية | |
| MX2021010152A (es) | Moduladores de la expresion de malat1. | |
| MX2022007955A (es) | Regimenes de dosificacion de erdafitinib. | |
| EA201791420A1 (ru) | Соединения триазолопиримидина и их применения | |
| MX2020007369A (es) | Moduladores de la expresion de dnm2. | |
| AU2016380190A8 (en) | Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof | |
| ZA202004848B (en) | Modulators of irf4 expression | |
| EA202191358A1 (ru) | Новые соединения и их применение в лечении | |
| MX2020010721A (es) | Moduladores de la expresion de ezh2. | |
| PH12021551053A1 (en) | Modulators of irf5 expression | |
| MX2021010345A (es) | Compuestos de pirazolopiridina para la inhibición de ire1. |